Earnings per share for the last twelve months: Jilin Zhengye Biotechnology (ZYBT)

Public company logo of Jilin Zhengye Biotechnology (ZYBT)

The rolling 12-month earnings per share trend visualizes the financial trajectory, where the -0.20 mark indicates the profit level. Zhengye Biotechnology (ZYBT) develops its own vaccines, outsourcing only the logistics to external partners. Growth is driven by the modernization of Chinese farms and new swine pharmaceuticals. A strong team of virologists, motivated by scientific research grants, solidifies this success.

ZYBT (Zhengye Biotechnology) Net earnings per share (EPS TTM) history from 01/08/2025 to 11/17/2026

Analytical breakdowns for Zhengye Biotechnology (ZYBT)

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Summary company analytics:Zhengye Corp (ZYBT)
Flagship merchandise of Zhengye Corp

Professional managers utilize fundamental filters to assess real capital efficiency, where the trailing 12-month net income per share consolidates the final financial result of four quarters divided by the total number of securities. For Zhengye Biotechnology (ZYBT), this metric reflects the monetization of unique patents and biosanitary advantages; therefore, the trend in the trailing 12-month net income per share confirms the business resilience within the closed niche of veterinary vaccines.